Glaxo reports fall in turnover, sales - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Glaxo reports fall in turnover, sales

Oct 30, 2000

Glaxo India has reported disappointing results for the third quarter ended September 2000. The company has reported a fall in both turnover (by 4.74%) and net profit (by 4%) and this seen in the light of a 27% growth in the second quarter of the current year is disappointing. The net profit of the company stood at Rs 153.3 m on a turnover of Rs 2,361 m in the third quarter.

(Rs m)3QFQ003QFY01Change
Sales 2,479 2,361 -4.7%
Other Income 88 101 15.5%
Expenditure 2,246 2,156 -4.0%
Operating Profit (EBDIT) 233 205  
Operating Profit Margin (%)9.4%8.7% 
Interest 32 26 -18.4%
Depreciation 48 42 -13.7%
Profit before Tax 240 238 -0.7%
Other Adjustments   
Tax 80 85  
Profit after Tax/(Loss) 160 153 -4.1%
Net profit margin (%)6.4%6.5% 
Earnings per share*10.6910.25 

The company has attributed the depressed sales in the current quarter to the extended trade boycotts in certain southern states and reduced purchases by the trade in certain other states, primarily because of the changes in the sales tax in eastern and southern India.

For the first nine months the company’s total net profit works out to Rs 589 m and the turnover figures for the same period work out to Rs 7,061 m. These are in line with our full year turnover projection of Rs 10,050 m and net profit of Rs 850 m.

The stock quotes at Rs 431 which implies an earnings multiple of 32 times of nine months annualised FY01 earnings.

Equitymaster requests your view! Post a comment on "Glaxo reports fall in turnover, sales". Click here!


More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 7, 2021 (Close)


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks